PF-3052334 

PF-3052334 is an orally active, hepatically selective HMG-CoA reductase inhibitor with an IC₅₀ of 1.9 nM. PF-3052334 inhibits cholesterol synthesis, with IC₅₀ values ​​of 0.9 and 730 nM in hepatocytes and muscle cells, respectively. PF-3052334 can be used to study hypercholesterolemia^[1].

PF-3052334 (10 mg/kg, p.o., single dose) PF-3052334 significantly inhibits cholesterol synthesis at both 2-4 h and 4-6 h in hamsters^[1].
PF-3052334 (20 mg/kg, p.o., once daily for 7 days) causes low density lipoprotein (LDL) reduction in guinea pigs with an ED₅₀ of 3.6 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

533.57

C₂₈H₃₃FN₃NaO₅

887702-61-6

O=C(O[Na])C[C@H](O)C[C@H](O)CCC1=C(C(C)C)C(C(NCC2=CC=C(C=C2)C)=O)=NN1C3=CC=C(C=C3)F

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pfefferkorn JA, et al. Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3 R, 5 R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2 H-pyrazol-3-yl]-3, 5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia. Journal of medicinal chemistry. 2008 Jan 10;51(1):31-45.